Cover Image

Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.

Show other versions (1)

<p class="MsoNormal" style="margin: 1pt 7.0865pt; text-align: justify;"><strong><span style="font-weight: bold; font-family: Tahoma;">Background</span></strong><span style="font-family: Tahoma;"><strong>:</strong>...

Full description

Saved in:

Bibliographic Details
Main Authors:	Leslie Pérez Ruiz (Author), Ana María Ramos Cedeño (Author), José Cabrera Gómez (Author), Nancy Echazábal Santana (Author), Hailen Bobillo López (Author)
Format:	Book
Published:	Centro Provincial de Información de Ciencias Médicas. Cienfuegos, 2007-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.
by: Leslie Pérez Ruiz, et al.
Published: (2007)

Using Recombinant Interferon Alpha-2b in Pediatric Practice
by: Yu.V. Marushko, et al.
Published: (2016)

IMMUNOMODULATING THERAPY BY RECOMBINANT ALPHA-2B INTERFERON AMONG CHILDREN WITH TIMOMEGALIA
by: L.A. Nikulin, et al.
Published: (2007)

IMMUNOMODULATING THERAPY BY RECOMBINANT ALPHA-2B INTERFERON AMONG CHILDREN WITH TIMOMEGALIA
by: L.A. Nikulin, et al.
Published: (2007)

Problems of interchangeability of systemic interferons for treatment of multiple sclerosis
by: I. I. Snegireva, et al.
Published: (2018)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
by: Cocco E, et al.
Published: (2015)

Evaluation of ior ® Leukocim efficacy on patients with Neutropenia.
by: Ana María Ramos Cedeño, et al.
Published: (2007)

Evaluation of ior ® Leukocim efficacy on patients with Neutropenia.
by: Ana María Ramos Cedeño, et al.
Published: (2007)

Vaginal biocenosis in pregnant women with recurrent bacterial vaginosis after treatment with recombinant human interferon alpha-2b
by: A. V. Podgornaya, et al.
Published: (2019)

Levels of circulating cytokines in children with multiple sclerosis with different effectiveness of interferon therapy
by: T. V. Radygina, et al.
Published: (2024)

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis
by: Slobodan M Jankovic
Published: (2010)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
by: Làzaro Aurelio Vàzquez Gòmez, et al.
Published: (2022)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
by: Mahe J, et al.
Published: (2013)

Contribution of human recombinant Interferon-Alpha 2b treatment in symptomatic and asymptomatic patients with SARS-CoV-2 virus infection
by: Cristobal Gonzáles-Losada, et al.
Published: (2022)

ANTIPROLIFERATIVE ACTIVITY OF RECOMBINANT HUMAN INTERFERON ALPHA2B ON ESTROGEN POSITIVE HUMAN BREAST CANCER MCF-7 CELL LINE
by: Ratih Asmana Ningrum, et al.
Published: (2015)

The Effectiveness of Complex Use of Inosine Pranobex and Recombinant Interferon-
by: E. N. Simovanyan, et al.
Published: (2015)

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN
by: L. M. Kuzenkova, et al.
Published: (2013)

QUALITY OF LIFE IN ADOLESCENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA-1A FOR SUBCUTANEOUS INJECTION
by: A.N. Platonova, et al.
Published: (2009)

QUALITY OF LIFE IN ADOLESCENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA-1A FOR SUBCUTANEOUS INJECTION
by: A.N. Platonova, et al.
Published: (2009)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
by: Rahil Sadat Shahtaheri, et al.
Published: (2018)

Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b
by: Farah Waleed Mahmood, et al.
Published: (2019)

Successful treatment of provisional cutaneous mastocytosis with interferon alpha
by: Andrea Rosario, et al.
Published: (2016)

Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon
by: Chen C, et al.
Published: (2018)

Análise de interferon humano recombinante presente em formulações farmacêuticas | Recombinant human interferon analysis in pharmaceutical formulations
by: Sinéa Mendes de Andrade, et al.
Published: (2017)

Evaluation of neuroprotective effects of alpha-tocopherol in cuprizone-induced demyelination model of multiple sclerosis
by: Nilesh Kumar Mitra, et al.
Published: (2020)

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab
by: Florian Ottenlinger, et al.
Published: (2016)

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
by: Elina Järvinen, et al.
Published: (2019)

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
by: Bloomgren G, et al.
Published: (2012)

Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)
by: Sara Moqbil, et al.
Published: (2022)

The role of plasmacytoid dendritic cells and interferon-alpha in the immunopathogenesis of psoriasis
by: Rafael Denadai
Published: (2013)

Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review
by: Gita Faghihi, et al.
Published: (2015)

Prevention of Adenovirus Infection with Recombinant Interferon 2b Medication in Preschool Institutions
by: L. V. Osidak, et al.
Published: (2016)

USE OF INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS: EFFICACY, SAFETY AND ADHERENCE TO THERAPY
by: O.V. Bykova, et al.
Published: (2009)

USE OF INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS: EFFICACY, SAFETY AND ADHERENCE TO THERAPY
by: O.V. Bykova, et al.
Published: (2009)

Axonal Damage in Pediatric Multiple Sclerosis
by: Nancy L Kuntz
Published: (2015)

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a
by: Reynaldo J.S.P. de Souza, et al.
Published: (2001)

Evaluation of recombinant human interferon beta 1b by liquid chromatography methods and bioassay
by: Francielle Santos da Silva, et al.
Published: (2019)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020)

Impairment, disability and fatigue in multiple sclerosis
by: Shahnaz Shahrbanian, et al.
Published: (2018)

CLINICALLY ISOLATED SYNDROME IN CHILDREN AND ADOLESCENTS - RISK FACTORS FOR MULTIPLE SCLEROSIS AND PROSPECTS OF USING INTRAMUSCULAR INTERFERON β-1A
by: O.V. Bykova, et al.
Published: (2010)